Invention Grant
![4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same](/docs/US/2019-09-03/US10399988B2/abs.jpg.600x600.jpg)
- Patent Title: 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
-
Application No.: US16097646Application Date: 2017-07-07
-
Publication No.: US10399988B2Publication Date: 2019-09-03
- Inventor: Youn-Jung Yoon , Jung-Eun Park , Yeon-Jung Park , Min-June Shim , Keuk-Chan Bang , Joon-Seok Park
- Applicant: Daewoong Pharmaceutical Co., Ltd.
- Applicant Address: KR Gyeonggi-do
- Assignee: Daewoong Pharmaceutical Co., Ltd.
- Current Assignee: Daewoong Pharmaceutical Co., Ltd.
- Current Assignee Address: KR Gyeonggi-do
- Agency: Marshall, Gerstein & Borun LLP
- Priority: KR10-2016-0086257 20160707
- International Application: PCT/KR2017/007281 WO 20170707
- International Announcement: WO2018/009017 WO 20180111
- Main IPC: C07D487/04
- IPC: C07D487/04 ; A61K31/519 ; C07D519/00 ; A61P35/00
![4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same](/abs-image/US/2019/09/03/US10399988B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same, wherein the 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing them not only have BTK inhibitory activity but also has remarkably high selectivity for the inhibitory activity of BTK vs. ITK, and thereby can be usefully used for the prevention or treatment of autoimmune diseases or cancers as BTK inhibitors.
Public/Granted literature
Information query
